A potential paradigm shift
in the treatment of pediatric and other cancers
Our lead compound SP-2577 represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.
Moreover, our discovery may also apply to cancers such as prostate, breast, ovarian, and other conditions like leukemia.
Salarius is the recipient of a 3-year $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is housed in the Johnson & Johnson Jlabs@TMC facility in Houston, Texas and receives support from organizations like the National Pediatric Cancer Foundation.